We report the 1 st case of severe, symptomatic hypocalcemia after denosumab (RANKL inhibitor) treatment in a peritoneal dialysis patient with secondary hyperparathyroidism and osteoporosis. A 58year-old Caucasian female has been receiving chronic ambulatory peritoneal dialysis for four years secondary to polycystic kidney disease. Laboratory studies revealed: albumin-corrected calcium 9.0 mg/dL, phosphorus 5 mg/dL, alkaline phosphatase (ALP) 58 U/L [normal, 40-105], albumin 3.4 gm/dL [normal, 3.6-5.4] and intact parathyroid hormone (PTH) 315 pg/mL [normal, 40-72]. Marked osteoporosis was noted on the DXA scan, preventing her from renal transplantation considerations. She had failed conventional medical treatment, including per os calcium, monthly ergocalciferol (50,000 units/month), activated vitamin-D analog (doxercalciferol) and renal-failure adjusted alendronate (70 mg twice a month). She was started on subcutaneous denosumab 60 mg every 6 months. After her first dose, she developed a progressive drop of calcium, phosphorus, bicarbonate and magnesium, in spite of massive escalation of doxercalciferol and calcium supplementation. Hypocalcemia nadired at 6.3 mg/dL with symptomatic tetany, requiring a brief hospitalization approximately 7 weeks after denosumab treatment. Her elevated PTH rose further transiently (647 pg/mL), along with ALP (123 U/L). Bone-mineral parameters normalized approximately 3 months after denosumab administration. The observed phenomenon resembled the phenotype of "hungry bone syndrome" observed after surgical parathyroidectomy. Conclusion. Treatment decisions based on bone densitometry results alone are not transposable between patients with or without end-stage renal disease. Denosumab may lead to critical hypocalcemia in dialysis patients and further aggravate existing secondary hyperparathyroidism.
Introduction
Bisphosphonates bind bone minerals and are absorbed by mature osteoclasts, inducing osteoclast apoptosis and suppressing resorption (1, 2) . Due to the potential renal toxicity of bisphosphonates, there has been some interest in the use of denosumab, a receptor activator of nuclear factor (NF-κB) ligand (RANKL) inhibitor for treatment of osteoporosis in patients with renal impairment. Until recently, denosumab, as per the manufacturer's instructions, did not require dosage adjustments for renal impairment (3) . Published experience of the use of denosumab in end-stage renal disease (ESRD) is, however, very scant. One preliminary study of 8 hemodialysis patients (4) and another case report have raised concerns about severe hypocalcemia in hemodialysis patients (5) . We report the 1 st case of severe symptomatic hypocalcemia secondary to denosumab in a peritoneal dialysis-dependent patient with controlled secondary hyperparathyroidism.
Case Study
Our index patient was a 58-year-old Caucasian female with end-stage renal disease (ESRD) secondary to polycystic kidney, who had been on chronic ambulatory peritoneal dialysis (CAPD) for 4 years and doing well on renal replacement therapy, except for a progressive height loss. A dual-energy x-ray absorptiometry (DXA) scan was obtained in August of 2011, revealing significant osteoporosis (Table. 2). She denied a prior history of osteoporosis or any fracture. Except for continued tobacco abuse, she denied risk factors such as glucocorticoid use, seizure medications or a family history of osteoporosis. She had been on a vitamin D supplement 50,000 International Units once a month and was previously on over-the counter calcium-carbonate as phosphorus binder; however, she developed transient hypercalcemia and calcium carbonate was discontinued. She was placed on alendronate (Fosamax®) which she had been taking without any difficulty. However, she noted further height loss over the ensuing months and was also rejected by the renal transplant team, citing her severe osteoporosis ruling out considerations of renal transplant eligilibilty. Co-morbid issues associated with her ESRD included secondary hyperparathyroidism and hyperphosphatemia, renal anemia with functional iron deficiency and chronic hypoalbuminemia and hypokalemia associated with peritoneal dialysis. Other co-morbidities included a prior cerebrovascular accident with no residual deficit, wellcontrolled hypertension, allergic rhinitis, chronic anxiety, history of colonic polyps and arteriovenous malformations and vitamin-D deficiency requiring replacement. For chronic metabolic acidosis, she was taking potassium-citrate on a long-term basis.
In terms of ESRD, she had done reasonably well on a CAPD regimen of 2 liters x 4 exchanges with 1.5% dextrose solution. Return volumes were always satisfactory, resulting in a net ultrafiltration of (6) . Indications since then have been expanded to include increasing bone mass in patients at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer or adjuvant aromatase inhibitor therapy for breast cancer (Approval September 2011), and to increase bone mass in men with osteoporosis at high risk for fracture (Approval September 2012). As Xgeva®, Denosumab is also approved for prevention of skeletal-related events in patients with bone metastases from solid tumors with the exception of Multiple Myeloma (Approval November 2010).
Osteoclast differentiation factor, also called receptor activator of nuclear factor (NF-κB) ligand (RANKL), stimulates the differentiation of osteoclast progenitors into osteoclasts. Osteoprotegerin acts as a natural soluble decoy receptor to bind RANKL and thus, reducing RANKL binding to RANK and reducing bone resorption. Denosumab is a full length human monoclonal antibody of IgG2 subtype mimicking the action of natural osteoprotegerin by binding to and inhibiting RANKL. It exhibits a nonlinear, dose dependent pharmacokinetics after subcutaneous injection, with levels peaking in 7-21 days (7) . As expected for an IgG antibody, it is not cleared by the kidneys and, therefore, does not require dosage adjustments for renal impairment (4) . Denosumab administration results in rapid and sustained decrease for markers of bone resorption; in one study, an 85% reduction in serum Ctelopeptide of type I collagen (a bone resorption marker reflecting osteoclast activity) was seen in 3 days, with a peak reduction in one month (3) . Therefore, this potent and long lasting effect on bone remodeling raises the concerns for hypocalcemia. This was clinically noted in the FREEDOM trial in which within one month, 1.7% of subjects from the drug arm experienced calcium values below 8.5 mg/dl as opposed to 0.4% in the placebo arm (6, 8) . It should be noted that in the FREEDOM Trial, only 73 women had a calculated creatinine clearance 15 to 29 mL/min and none had end-stage renal dysfunction (< 15 mL/min) and, therefore, it was underpowered to study the hypocalcemic effects of denosumab in severe CKD or terminal renal failure (9) . In patients with normal kidney function, nadir in serum calcium is noted on day 10(3). This hypocalcemic effect appears to be more pronounced in patients with renal insufficiency. In the FREEDOM Extension study of 4,550 subjects, a more marked reduction in serum calcium was noted in subjects with renal insufficiency: -5.5% reduction in mean serum calcium in subjects with creatinine clearance < 30 mL/min vs. -3.1% in subjects with creatinine clearance ≥ 30 mL/min at approximately day 10 (3, 10) . In another study of 55 patients with various degrees of renal impairment, severe and persistent hypocalcemia was noted in subjects with severe CKD (GFR <30 mL/min/1.73 m 2 ), which was especially profound with kidney failure requiring hemodialysis. 5 out of 8 dialysis dependent patient developed hypocalcemia (serum calcium < 8 mg/dL) and calcium dropped below 7.5 mg/dL in 2 of them(4). Additionally, McCormick et al. also recently reported a case of severe hypocalcemia with denosumab in a hemodialysis patient (5) .
Interestingly, a recent case report mentioned successful treatment of immobilization-related hypercalcemia with denosumab in a patient with advanced renal insufficiency (11) . In a boy with fibrous dysplasia, denosumab did not impair healing of a femoral fracture that occurred while on treatment during which, similar to our case presented here, secondary hyperparathyroidism developed (12) .
Clinical experience thus far suggests that denosumab can result in a rapid and sustained reduction in serum calcium in the presence of severe renal insufficiency or renal failure. This effect may be more pronounced in patients with a history of secondary hyperparathyroidism, perhaps as a function of a larger osteoblast mass in these patients. Inhibition of osteoclastic activity by denosumab may result in excess unopposed osteoblastic activity and resultant severe sustained hypocalcemia, analogous to what we observe as "hungry bone syndrome" after surgical parathyroidectomy (13, 14) . This sustained hypocalcemia can also (further) elevate PTH and aggravate existing secondary hyperparathyroidism.
Of note, our patient with existing secondary hyperparathyroidism had previously been treated with a bisphosphonate (alendronate) before denosumab had been administered while 1,25-dihydroxy vitamin D and 25-OH vitamin D levels were within normal range, possibly suggesting an additive effect of both antiresorptive agents. Our patient had PTH in the target range, normal calcium and vitamin D levels at baseline, and was already receiving calcium supplementation and activated vitamin D analog is unclear at this time. Potentially, a patient with osteoporosis and hypercalcemia may be the ideal candidate, but this issue is clearly not well studied or understood at this point.
Conclusion
Treatment decisions based on bone densitometry results alone (rather than bone biopsy) are not transposable between patients with or without end-stage renal disease. An antiresorptive agent such as denosumab may lead to critical and prolonged hypocalcemia in dialysis patients as observed in this case and further aggravate existing secondary hyperparathyroidism. Additional research is needed to identify the highest risk patients and effective strategies to minimize this serious side effect. 
